Navigation Links
25 percent don't complete recommended breast cancer treatment
Date:4/9/2013

April 9, 2013

ANN ARBOR, Mich. One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.

Five years of daily tamoxifen or aromatase inhibitors -- two types of endocrine therapy that are taken as a pill -- is recommended for many women whose breast cancer expresses the hormones estrogen or progesterone. The drugs have been shown to reduce cancer recurrence and increase survival. And recent studies suggest there may be even more benefit for some women to continue this therapy for 10 years.

Despite this, the study of 743 women eligible for endocrine therapy found that about 11 percent never initiated the treatments and 15 percent stopped taking it early. Results appear online in Breast Cancer Research and Treatment.

"We're doing well with women taking endocrine therapy, but there's work to do," says lead study author Christopher Friese, Ph.D., R.N., assistant professor at the University of Michigan School of Nursing. "If guidelines begin to shift so that some women at high risk of breast cancer recurring need 10 years of endocrine therapy, then the number of women who persist with treatment will likely worsen. We need to develop better ways of supporting women through this therapy."

The most common reason patients said they either discontinued or never started endocrine therapy was side effects. Many women experience menopause-like symptoms such as hot flashes or vaginal dryness, and both types of drugs, more commonly the aromatase inhibitors, can cause joint pains.

The study surveyed women in the Detroit and Los Angeles areas who were diagnosed with breast cancer and reported to Surveillance, Epidemiology and End Results, or SEER, tumor registries. Women were surveyed at about nine months after their diagnosis and again about four years later with questions about their use of tamoxifen or any type of aromatase inhibitor.

Women who expressed more worry about their cancer recurring were more likely to complete endocrine therapy, as were women who already took medication regularly.

Women who reported receiving less information about endocrine therapy were less likely to begin taking it, suggesting that doctors need to address patient education before treatment starts. Women who saw a breast surgeon as their primary follow-up, rather than a medical oncologist, were also less likely to begin endocrine therapy.

"It was particularly interesting that greater fear of recurrence was associated in our patient sample with greater adherence to endocrine therapy," says senior study author Jennifer J. Griggs, M.D., M.P.H., professor of internal medicine at the U-M Medical School and a medical oncologist who sees patients with breast cancer at the U-M Comprehensive Cancer Center.

"We don't want our patients living under a cloud of fear, so we need to develop creative ways to both reassure and motivate them. This means providing better education about the importance of staying on these medications and partnering with primary care and cancer doctors to help patients manage symptoms," Griggs adds.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Roadmap to 25 percent reduction in premature deaths From RHD in the under 25s by 2025 published
2. Ready for debut: Fruit-juice-infused chocolate with 50 percent less fat
3. Nearly 30 Percent of Americans Have High Blood Pressure: CDC
4. CodingCertification.Org in the Top 5 Percent in LinkedIn Most Viewed Profiles in 2012
5. Common gene variants explain 42 percent of antidepressant response
6. Port Washington, NY Dentist Dr. Doron Keren of Gold Coast Family Dental Receives 98 Percent Satisfaction Rating from Patient Reviews
7. Newly incarcerated have 1 percent acute hepatitis C prevalence
8. Sports and recreation injuries drop 12 percent for children ages 5-14 during past decade
9. Telestroke program increases access to stroke care by 40 percent
10. Mortality for acute aortic dissection near 1 percent per hour during initial onset
11. Colonoscopy Cuts Advanced Cancer Risk by 70 Percent: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: